Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Tumor-agnostic HER2 therapy reaches Europe.
The European Commission has approved trastuzumab deruxtecan (T-DXd, Enhertu) for previously treated HER2-positive (IHC 3+) unresectable/metastatic solid tumors, regardless of the tumour’s site of origin.
Why this matters: The approval pools evidence from DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02, moving HER2 from an organ-specific biomarker to a true pan-tumor therapeutic target.
Key efficacy:
- DESTINY-PanTumor02: ORR 52.3%, median DoR 21.1 months
- DESTINY-Lung01 (HER2 IHC3+): ORR 52.9%
- DESTINY-CRC02 (HER2 IHC3+): ORR 46.9%
The biggest clinical message isn’t just another approval. It’s that routine HER2 testing may now become relevant across many metastatic solid tumors, not only breast, gastric and lung cancers.
Precision oncology is becoming increasingly biomarker-first rather than organ-first. Will this change your HER2 testing strategy?”
You can also read:
